Pet Medicus Laboratories


Public lists: Pharma Startups (4732)

Pet Medicus Laboratories is a specialty pharmaceutical company that is engaged in the formulation, clinical testing, federal registration, manufacture, and sale of drug products for the companion animal market.

Pet Medicus Laboratories is a specialty pharmaceutical company that is engaged in the formulation, clinical testing, federal registration, manufacture, and sale of drug products for the companion animal market.

Company (Alive / Active)

Phone: 605-271-8007

Fax:

101 South Main Avenue
Sioux Falls, 57104
South Dakota, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Pet Medicus Laboratories $0M Nov 30, 2018
See all 13 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Pet Medicus Laboratories Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

AkaRx

Paramus, New Jersey, United States
Alive / ActiveAkaRx develops therapeutic products including avatrombopag, which is an investigational oral thrombopoietin receptor agonist.Login to see details

Somaxon Pharmaceuticals

San Diego, California, United States
AcquiredSomaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area. Our lead product candidate is Silenor (doxepin) for the treatment of insomnia. Silenor is a sleep-specific, low-dose (3mg and 6mg), oral tablet formulation of doxepin that is patent-protected for use in insomnia. In contrast...Show allLogin to see details
See all 13 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)